BIOS - BioScrip, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9000
-0.1800 (-8.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0800
Open2.0900
Bid1.8900 x 4000
Ask1.9100 x 21500
Day's Range1.8600 - 2.1300
52 Week Range1.8600 - 4.1400
Volume4,206,337
Avg. Volume1,156,968
Market Cap243.494M
Beta (3Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.4920
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.68
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of BIOS earnings conference call or presentation 15-Mar-19 1:00pm GMT

    Q4 2018 BioScrip Inc Earnings and Definitive Merger Agreement with Option Care Call

  • Moody's5 days ago

    BioScrip, Inc. -- Moody's places BioScrip's ratings under review for upgrade following the announced merger with HC Group Holdings

    Moody's Investors Service ("Moody's") today placed the ratings of BioScrip, Inc. (BioScrip), including the Caa1 Corporate Family Rating (CFR), under review for upgrade. This follows the announcement that BioScrip will merge with HC Group Holdings III, Inc.(dba Option Care). BioScrip will issue common stock to Option Care in an all-stock deal.

  • MarketWatch5 days ago

    BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish

    Shares of BioScrip Inc. tumbled 9.0% toward a 9-month low in midday trade Monday, extending the sharp reversal suffered early in the previous session as investors digested the terms of the company's merger deal with Option Care Enterprises Inc. On Friday, the stock soared as much as 71% in premarket trade, and as much as 8.0% during the regular session, before pulling a sharp U-turn to close down 20.3%. Canaccord Genuity analyst Richard Close said that investors may have to suffer some short-term pain, given the disappointment that BioScrip shareholders will own just 20% of the post-merger company, but he remains bullish given the long-term potential. "The need for scale in health care is increasingly paramount as the provider and payer markets consolidate and reimbursement risk is always present," Close wrote in a research note. "Thus, having scale is a significant advantage as [BioScrip] seeks to negotiate rates and drive sustained operating results." The stock has tumbled 35.5% year to date, while the S&P 500 has climbed 12.7%.

  • BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract
    Zacks5 days ago

    BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

    The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.

  • Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?
    Zacks5 days ago

    Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?

    Investors need to pay close attention to BioScrip (BIOS) stock based on the movements in the options market lately.

  • ACCESSWIRE5 days ago

    Merger Agreement and Earnings Review in this Comprehensive Report on BioScrip

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on BioScrip Inc. (BIOS), a provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. Recently, BioScrip and Option Care jointly announced a definitive merger agreement, which will create the nation's preeminent home infusion company and transform the industry. Option Care's signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support, and care coordination.

  • Why Adobe, BioScrip, and Ascena Retail Group Slumped Today
    Motley Fool8 days ago

    Why Adobe, BioScrip, and Ascena Retail Group Slumped Today

    Earnings and other bad news kept these stocks out of today's rally.

  • Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool8 days ago

    Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript

    BIOS earnings call for the period ending December 31, 2018.

  • Why BioScrip Stock Popped and Then Dropped Today
    Motley Fool8 days ago

    Why BioScrip Stock Popped and Then Dropped Today

    BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.

  • TheStreet.com8 days ago

    Infusion Therapy Firm BioScrip to Buy Rival Option Care

    agreed to buy rival Option Care Enterprises, creating one of the largest independent home-therapy companies in the U.S. On completion of the all-stock deal, MDP funds and WBA will own roughly 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder, the companies said. Option Care CEO John Rademacher will lead the combined company.

  • MarketWatch8 days ago

    BioScrip's stock soars after merger deal with Option Care, owned by Walgreens and Madison Dearborn

    Shares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.

  • Associated Press8 days ago

    BioScrip: 4Q Earnings Snapshot

    The Denver-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • GlobeNewswire8 days ago

    BioScrip Reports Fourth Quarter and Full Year 2018 Financial Results

    DENVER, March 15, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.

  • GlobeNewswire8 days ago

    Home and Alternate Site Infusion Therapy Providers BioScrip and Option Care to Merge

    DENVER and BANNOCKBURN, Ill., March 15, 2019 (GLOBE NEWSWIRE) --  BioScrip, Inc. (BIOS) (“BioScrip”) and Option Care Enterprises, Inc. (“Option Care”), the nation’s largest independent providers of home and alternate treatment site infusion therapy services, today announced that they have entered into a definitive merger agreement. The combination is expected to create a leading independent provider with the national reach, comprehensive therapy offering and financial capacity to succeed in the attractive and growing home and alternate site infusion services segment of the $100 billion U.S. infusion market.

  • ACCESSWIRE8 days ago

    BioScrip, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2019 / BioScrip, Inc. (NASDAQ: BIOS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 15, 2019, 2018 at 9:00 AM ...

  • GlobeNewswire9 days ago

    BioScrip Reschedules Release of Fourth Quarter and Full Year 2018 Financial Results and Conference Call

    DENVER, March 13, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.

  • What Kind Of Shareholders Own BioScrip, Inc. (NASDAQ:BIOS)?
    Simply Wall St.15 days ago

    What Kind Of Shareholders Own BioScrip, Inc. (NASDAQ:BIOS)?

    A look at the shareholders of BioScrip, Inc. (NASDAQ:BIOS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...

  • GlobeNewswire26 days ago

    BioScrip Schedules Release of Fourth Quarter and Full Year 2018 Financial Results and Conference Call

    DENVER, Feb. 25, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Macy's, Leggett & Platt, Tyler Technologies, BioScrip, DXC Technology, and STERIS plc — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    BioScrip to Present at the 37th Annual J.P. Morgan Healthcare Conference

    DENVER, Jan. 03, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.

  • Here is What Hedge Funds Think About BioScrip Inc. (BIOS)
    Insider Monkey3 months ago

    Here is What Hedge Funds Think About BioScrip Inc. (BIOS)

    Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]

  • Why Is BioScrip (BIOS) Up 18.7% Since Last Earnings Report?
    Zacks4 months ago

    Why Is BioScrip (BIOS) Up 18.7% Since Last Earnings Report?

    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • ACCESSWIRE4 months ago

    Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix

    CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.

  • GlobeNewswire4 months ago

    BioScrip to Host Analyst and Investor Day

    DENVER, Nov. 26, 2018 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Seeing New Highs On Monday

    CORAL GABLES, FL / ACCESSWIRE / November 26, 2018 / Healthcare stocks remain popular during the latest bout of selling pressure within the broader markets. The Frost & Sullivan Healthcare and Life Sciences experts are predicting big disruptions, transformationsand innovations in the coming years as the healthcare industry continues to overhaul outmoded business models. "Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally," noted Sandeep Sinha, Vice President & Head, Healthcare and Life Sciences, Frost & Sullivan.